We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Foresee Home for Monitoring Age Related Macular Degeneration (AMD) (Foresee Home)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01010997
First Posted: November 10, 2009
Last Update Posted: July 31, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Notal Vision Ltd
  Purpose
The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with AMD. However, the device has ability to detect the development of the lesion post treatment and therefore to asses in determination of the next treatment.

Condition Intervention
Age Related Macular Degeneration Device: Foresee Home

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Foresee Home for Monitoring Age Related Macular Degeneration (AMD)

Resource links provided by NLM:


Further study details as provided by Notal Vision Ltd:

Primary Outcome Measures:
  • To investigate the FORESEE HOME ability to diagnose AMD in different stages [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • To investigate the correlation between visual fields (VF) defects map generated by the FORESEE HOME and features of the choroidal neovascular lesions (CNV) demonstrated by Optical Coherence Tomography(OCT). [ Time Frame: 1 year ]

Enrollment: 10
Study Start Date: December 2009
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Dry AMD
Intermediate AMD subjects
Device: Foresee Home
using the Foresee home device
Wet - treated AMD
AMD subjects under treatments
Device: Foresee Home
using the Foresee home device

Detailed Description:

The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with AMD. However, the device has ability to detect the development of the lesion post treatment and therefore to asses in determination of the next treatment.

The OCT May be use as well to identify choroidal neovascularization (CNV). Comparison between the two methods will allow better understanding of both devices.

The FORESEE HOME can use as an assessment tool for the progression and success of the treatment given to AMD lesions. Therefore, evaluation the size and the location of the treated lesions may serve as an additional tool.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
AMD subjects
Criteria

Inclusion Criteria:

  • Capable and willing to sign a consent form and participate in the study
  • Subjects diagnosed as CNV under treatment or Intermediate AMD in at least one eye
  • Did not perform more then 10 anti- VEGF injections
  • Age >50 years
  • VA with habitual correction >6/45 in the study eye
  • Computer users

Exclusion Criteria:

  • Evidence of macular disease other than AMD or glaucoma in the study eye
  • Presence of any significant media opacity that precludes a clear view of the macular area as identified in the study eye by biomicroscopy,
  • Any non-macular related ocular surgery performed within 3 months prior to study entry in the target eye
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01010997


Locations
Israel
Naharia Hospital
Naharia, Israel
Sponsors and Collaborators
Notal Vision Ltd
Investigators
Principal Investigator: Eliezer Kraus, MD Naharia Hospital
  More Information

Responsible Party: Notal Vision Ltd
ClinicalTrials.gov Identifier: NCT01010997     History of Changes
Other Study ID Numbers: FORESEE HOME- 02
75909 ( Other Identifier: Local IRB )
First Submitted: November 8, 2009
First Posted: November 10, 2009
Last Update Posted: July 31, 2012
Last Verified: July 2012

Keywords provided by Notal Vision Ltd:
AMD, CNV

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases